EP1368024A4 - Traitement de la restenose - Google Patents

Traitement de la restenose

Info

Publication number
EP1368024A4
EP1368024A4 EP02707999A EP02707999A EP1368024A4 EP 1368024 A4 EP1368024 A4 EP 1368024A4 EP 02707999 A EP02707999 A EP 02707999A EP 02707999 A EP02707999 A EP 02707999A EP 1368024 A4 EP1368024 A4 EP 1368024A4
Authority
EP
European Patent Office
Prior art keywords
restenosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02707999A
Other languages
German (de)
English (en)
Other versions
EP1368024A1 (fr
Inventor
Alan Husband
Graham Edmund Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marshall Edwards Inc
Original Assignee
Novogen Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR3770A external-priority patent/AUPR377001A0/en
Priority claimed from AUPR5926A external-priority patent/AUPR592601A0/en
Application filed by Novogen Research Pty Ltd filed Critical Novogen Research Pty Ltd
Publication of EP1368024A1 publication Critical patent/EP1368024A1/fr
Publication of EP1368024A4 publication Critical patent/EP1368024A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP02707999A 2001-03-16 2002-03-15 Traitement de la restenose Withdrawn EP1368024A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPR377001 2001-03-16
AUPR3770A AUPR377001A0 (en) 2001-03-16 2001-03-16 Treatment of restenosis
AUPR5926A AUPR592601A0 (en) 2001-06-26 2001-06-26 Treatment of restenosis
AUPR592601 2001-06-26
PCT/AU2002/000288 WO2002074307A1 (fr) 2001-03-16 2002-03-15 Traitement de la restenose

Publications (2)

Publication Number Publication Date
EP1368024A1 EP1368024A1 (fr) 2003-12-10
EP1368024A4 true EP1368024A4 (fr) 2009-03-18

Family

ID=25646619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02707999A Withdrawn EP1368024A4 (fr) 2001-03-16 2002-03-15 Traitement de la restenose

Country Status (3)

Country Link
EP (1) EP1368024A4 (fr)
JP (2) JP4256679B2 (fr)
WO (1) WO2002074307A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
EP1503751A4 (fr) * 2002-04-09 2007-08-01 Novogen Res Pty Ltd Procedes therapeutiques et compositions associees contenant des structures isoflav-3-ene et isoflavan
ES2360130T3 (es) * 2005-03-24 2011-06-01 Novogen Research Pty. Ltd. Dímeros de isoflavonoides.
WO2007010342A1 (fr) * 2005-07-15 2007-01-25 Sahajanand Biotech Private Limited Dispositifs medicaux implantables comprenant un flavonoide ou un derive de celui-ci pour la prevention de la restenose
EP2314295B1 (fr) * 2005-07-29 2015-01-28 Resverlogix, Inc Compositions pharmaceutiques pour la prevention et le traitement de maladies complexes et leur administration par des dispositifs medicaux inserables
CA2676984C (fr) 2007-02-01 2015-03-17 Resverlogix Corp. Composes destines a la prevention et au traitement de maladies cardiovasculaires
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
CA2711103C (fr) 2008-06-26 2016-08-09 Resverlogix Corp. Procedes de preparation de derives de quinazolinone
KR20110101135A (ko) * 2008-10-22 2011-09-15 노보겐 리서치 피티와이 리미티드 예정 세포 사멸을 유도하는 방법
TWI472525B (zh) 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
WO2010106436A2 (fr) 2009-03-18 2010-09-23 Resverlogix Corp. Nouveaux agents anti-inflammatoires
AU2010239266B2 (en) 2009-04-22 2015-01-22 Resverlogix Corp. Novel anti-inflammatory agents
CA2851996C (fr) 2011-11-01 2020-01-07 Resverlogix Corp. Compositions pharmaceutiques pour des quinazolinones substituees
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
CA2936012C (fr) 2014-02-07 2023-03-07 Novogen Limited Composes de benzopyrane fonctionnalises et leur utilisation
WO2016147053A1 (fr) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
KR102005237B1 (ko) * 2017-02-28 2019-07-30 서울대학교산학협력단 에쿠올 유도체를 생산하는 재조합 대장균 및 이를 이용한 에쿠올 유도체 합성 방법
BR112020021194A2 (pt) 2018-04-18 2021-03-23 Constallation Pharmaceuticals, Inc. moduladores de enzimas modificadoras de metila, composições e usos dos mesmos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
ES2997972T3 (en) 2019-07-24 2025-02-18 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2190411A1 (en) * 1972-06-27 1974-02-01 Blaise Rolland Derivs of 7-hydroxy isoflavones - vascular protectors, antiphlogistics and anti-allergics, prepd from a halocarboxylic acid and a 7-hydroxy isoflavone
WO1996031206A2 (fr) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
WO2000030665A1 (fr) * 1998-11-25 2000-06-02 Nutri Pharma Asa Composition contenant des proteines de soja, des fibres alimentaires et un compose de phytoestrogene et son utilisation pour la prevention et/ou le traitement de maladies cardiovasculaires
WO2001017986A1 (fr) * 1999-09-06 2001-03-15 Novogen Research Pty Ltd Compositions et methodes therapeutiques mettant en jeu des isoflavones et des analogues d'isoflavones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AU5440799A (en) * 1998-09-17 2000-04-10 Guido Schnyder Method and drug for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty
US6413546B1 (en) * 1999-03-18 2002-07-02 Indena, S.P.A. Tablets incorporating isoflavone plant extracts and methods of manufacturing them
AUPQ008399A0 (en) * 1999-04-28 1999-05-27 Novogen Research Pty Ltd Cariovascular applications
AUPQ008299A0 (en) * 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2190411A1 (en) * 1972-06-27 1974-02-01 Blaise Rolland Derivs of 7-hydroxy isoflavones - vascular protectors, antiphlogistics and anti-allergics, prepd from a halocarboxylic acid and a 7-hydroxy isoflavone
WO1996031206A2 (fr) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
WO2000030665A1 (fr) * 1998-11-25 2000-06-02 Nutri Pharma Asa Composition contenant des proteines de soja, des fibres alimentaires et un compose de phytoestrogene et son utilisation pour la prevention et/ou le traitement de maladies cardiovasculaires
WO2001017986A1 (fr) * 1999-09-06 2001-03-15 Novogen Research Pty Ltd Compositions et methodes therapeutiques mettant en jeu des isoflavones et des analogues d'isoflavones

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG HUEI-CHEN ET AL: "Antiproliferative effect of baicalein, a flavonoid from a Chinese herb, on vascular smooth muscle cell", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL, vol. 251, no. 1, 1 January 1994 (1994-01-01), pages 91 - 93, XP002349489, ISSN: 0014-2999 *
See also references of WO02074307A1 *
TRAXLER P ET AL: "STRATEGIES TOWARD THE DESIGN OF NOVEL AND SELECTIVE PROTEIN TYROSINE KINASE INHIBITORS", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 82, no. 2/03, 10 June 1999 (1999-06-10), pages 195 - 206, XP000985237, ISSN: 0163-7258 *
TRIEU V N ET AL: "EGF-GENISTEIN INHIBITS NEOINTIMAL HYPERPLASIA AFTER VASCULAR INJURY IN A EXPERIMENTAL RESTENOSIS MODEL", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, NEW YORK, NY, vol. 35, no. 4, 1 April 2000 (2000-04-01), pages 595 - 605, XP001011807, ISSN: 0160-2446 *

Also Published As

Publication number Publication date
JP4256679B2 (ja) 2009-04-22
JP2009143908A (ja) 2009-07-02
EP1368024A1 (fr) 2003-12-10
WO2002074307A1 (fr) 2002-09-26
JP2004529907A (ja) 2004-09-30

Similar Documents

Publication Publication Date Title
EP1368024A4 (fr) Traitement de la restenose
EP1359864A4 (fr) Revetement de stent irradie
DE60236093D1 (de) Entfernbarer stent
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
FR15C0028I2 (fr) Fabrication de tiacumicine
DE50112209D1 (de) Stent
KR100695846B9 (ko) 암 치료
EP1583997A4 (fr) Elimination de photoresine
EP1567101A4 (fr) Methodes de traitement prophylactique
BR0205514B1 (pt) processos de tratamento de cabelo
DE60214255D1 (de) Schlussstück
EP1485109A4 (fr) Traitement vasculaire
EP1611120A4 (fr) Nouvelles m thodes de traitement des maladies inflammatoires
EP1461027A4 (fr) Traitement de la neoplasie
MA26341A1 (fr) Stents
DE60227963D1 (de) Behandlungssystem
NO20041968L (no) Anvendelse av cystationin
EP1389105A4 (fr) Methode de traitement
DE60222664D1 (de) Hautbehandlungsmittel
SE0301854L (sv) Antiigensättningsbehandling
DE50113918D1 (de) Quengel-Orthese
EP1401494A4 (fr) Traitement anti-tumoral
NO20015983D0 (no) Sangmikrofon
ATE333439T1 (de) Pflanzenkläranlage
FR2825893B3 (fr) Tunnel de traitement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090213

17Q First examination report despatched

Effective date: 20091120

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MARSHALL EDWARDS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120308